https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28831 Wed 11 Apr 2018 13:23:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26346 Wed 11 Apr 2018 13:23:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25795 Wed 11 Apr 2018 12:09:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42900 Tue 06 Sep 2022 15:14:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33809 -4). We did not find evidence that SNP genotype was influencing the DMR in this cohort. A smaller MHC DMR was also identified at HCG4B, and two non-MHC DMRs at PM20D1 on chr1 and ERICH1 on chr8 were also identified. Conclusions: The findings from this study confirm our previous results of a DMR at HLA-DRB1 and also suggest hypermethylation in an independent MHC locus, RNF39, is associated with MS. Taken together, our results highlight the importance of epigenetic factors at the MHC locus in MS independent of treatment, age and sex. Prospective studies are now required to discern whether methylation at MHC is involved in influencing risk of disease onset or whether the disease itself has altered the methylation profile.]]> Tue 03 Sep 2019 18:30:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32442 Thu 09 Dec 2021 11:04:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38628 + T cells of relapsing–remitting (RR) MS patients compared to healthy controls and identified differentially methylated regions (DMRs) in HLA-DRB1 and RNF39. This study aimed to investigate the DNA methylation profiles of the CD4⁺ T cells of progressive MS patients. DNA methylation was measured in two separate case/control cohorts using the Illumina 450K/EPIC arrays and data was analysed with the Chip Analysis Methylation Pipeline (ChAMP). Single nucleotide polymorphisms (SNPs) were assessed using the Illumina Human OmniExpress24 arrays and analysed using PLINK. Expression was assessed using the Illumina HT12 array and analysed in R using a combination of Limma and Illuminaio. We identified three DMRs at HTR2A, SLC17A9 and HDAC4 that were consistent across both cohorts. The DMR at HTR2A is located within the bounds of a haplotype block; however, the DMR remained significant after accounting for SNPs in the region. No expression changes were detected in any DMRs. HTR2A is differentially methylated in progressive MS independent of genotype. This differential methylation is not evident in RRMS, making it a potential biomarker of progressive disease.]]> Mon 29 Jan 2024 17:52:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35542 Mon 26 Aug 2019 15:28:04 AEST ]]>